Shu and colleagues (1) made a significant contribution to a growing body of evidence for the utilization of immunotherapy in the neoadjuvant setting for patients with resectable non-small cell lung cancer (Table 1) (2-4). Of 39 assessed patients, 31 were commenced on treatment consisting of Atezolizumab with nab-paclitaxel and carboplatin. After excluding two patients with colorectal cancer and brain metastasis, 29 underwent surgery with a curative intent. At the time of operation, three patients were deemed unresectable, with 26 patients achieving R0 resection. There was one (3%) mortality from pneumonia and respiratory failure, with major perioperative complications mostly related to neutropenia, liver dysfunction, and thrombocytopenia. P...
Abstract Background There are many studies on neoadjuvant immunotherapy for locally advanced non‐sma...
BackgroundIt remains uncertain whether neoadjuvant immune checkpoint inhibitor (nICI) is superior to...
OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for non-small cell lung...
While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has not...
There is a paucity of robust clinical evidence for the role of neoadjuvant immunotherapy in patients...
There is a paucity of robust clinical evidence for the role of neoadjuvant immunotherapy in patients...
Background: The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-small-cell ...
Background and objective Preliminary researches conformed that neoadjuvant immunotherapy combined wi...
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage n...
The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (...
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lu...
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lu...
Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in co...
Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lu...
Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in co...
Abstract Background There are many studies on neoadjuvant immunotherapy for locally advanced non‐sma...
BackgroundIt remains uncertain whether neoadjuvant immune checkpoint inhibitor (nICI) is superior to...
OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for non-small cell lung...
While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has not...
There is a paucity of robust clinical evidence for the role of neoadjuvant immunotherapy in patients...
There is a paucity of robust clinical evidence for the role of neoadjuvant immunotherapy in patients...
Background: The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-small-cell ...
Background and objective Preliminary researches conformed that neoadjuvant immunotherapy combined wi...
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage n...
The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (...
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lu...
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lu...
Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in co...
Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lu...
Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in co...
Abstract Background There are many studies on neoadjuvant immunotherapy for locally advanced non‐sma...
BackgroundIt remains uncertain whether neoadjuvant immune checkpoint inhibitor (nICI) is superior to...
OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for non-small cell lung...